Use of a rapid human primary cell-based disease screening model, to compare next generation products to combustible cigarettes.

Autor:	Simms L; Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL UK., Mason E; Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL UK., Berg EL; Eurofins Discovery, Inc., 111 Anza Blvd, Suite 414, Burlingame, CA 94010, USA., Yu F; Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL UK., Rudd K; Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL UK., Czekala L; Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL UK., Trelles Sticken E; Reemtsma Cigarettenfabriken GmbH, An Imperial Brands PLC Company, Albert-EinsteinRing-7, D-22761 Hamburg, Germany., Brinster O; Reemtsma Cigarettenfabriken GmbH, An Imperial Brands PLC Company, Albert-EinsteinRing-7, D-22761 Hamburg, Germany., Wieczorek R; Reemtsma Cigarettenfabriken GmbH, An Imperial Brands PLC Company, Albert-EinsteinRing-7, D-22761 Hamburg, Germany., Stevenson M; Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL UK., Walele T; Imperial Brands PLC, 121 Winterstoke Road, Bristol BS3 2LL UK.
Jazyk:	angličtina
Zdroj:	Current research in toxicology [Curr Res Toxicol] 2021 Aug 17; Vol. 2, pp. 309-321. Date of Electronic Publication: 2021 Aug 17 (Print Publication: 2021).
DOI:	10.1016/j.crtox.2021.08.003
Abstrakt:	A growing number of public health bodies, regulators and governments around the world consider electronic vapor products a lower risk alternative to conventional cigarettes. Of critical importance are rapid new approach methodologies to enable the screening of next generation products (NGPs) also known as next generation tobacco and nicotine products. In this study, the activity of conventional cigarette (3R4F) smoke and a range of NGP aerosols (heated tobacco product, hybrid product and electronic vapor product) captured in phosphate buffered saline, were screened by exposing a panel of human cell-based model systems using Biologically Multiplexed Activity Profiling (BioMAP® Diversity PLUS® Panel, Eurofins Discovery). Following exposure, the biological activity for a wide range of biomarkers in the BioMAP panel were compared to determine the presence of toxicity signatures that are associated with specific clinical findings. NGP aerosols were found to be weakly active in the BioMAP Diversity PLUS Panel (≤3/148 biomarkers) whereas significant activity was observed for 3R4F (22/148 biomarkers). Toxicity associated biomarker signatures for 3R4F included immunosuppression, skin irritation and thrombosis, with no toxicity signatures seen for the NGPs. BioMAP profiling could effectively be used to differentiate between complex mixtures of cigarette smoke or NGP aerosol extracts in a panel of human primary cell-based assays. Clinical validation of these results will be critical for confirming the utility of BioMAP for screening NGPs for potential adverse human effects. Competing Interests: Liam Simms, Elizabeth Mason, Fan Yu, Kathryn Rudd, Lukasz Czekala, Edgar Trelles Sticken, Oleg Brinster, Matthew Stevenson and Tanvir Walele were all current employees for Imperial Brands PLC at the time of submission. Imperial Brands PLC, who funded the work and was the sole sponsor of the project. Ellen L. Berg was the Eurofins Discovery contact who conducted the work and provided technical support to the project. None of the Imperial Brands personnel above have any known competing financial interests. (© 2021 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu